ERAS
Erasca, Inc.
NASDAQ · Healthcare · Biotechnology · US
$16.06
−1.24%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−19.0x
Market Cap
$5.62B
MomentumView details →
1D Return
−1.24%
YTD Return
+334.15%
RSI (14)
37.8
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−19.0x
Market Cap
$5.62B
RSI (14)
37.8
MomentumView details →
1D Return
−1.24%
YTD Return
+334.15%
SummaryUpdated Jun 1, 2026
Erasca, Inc. (NASDAQ:ERAS) is a clinical-stage biopharmaceutical company founded in 2018 and headquartered in San Diego, California. The company went public in July 2021 and focuses on developing targeted cancer therapies for patients with RAS/MAPK pathway-driven cancers. As a clinical-stage company, Erasca has no approved products or revenue yet, but maintains a robust pipeline of investigational drugs targeting various cancer types including lung cancer, colorectal cancer, acute myeloid leukemia, and brain tumors.
Similar companies
Latest newsMore news →
Bernstein Liebhard LLP announced an investigation into potential breaches of fiduciary duty by directors and officers of Erasca, Inc.9d agoThe U.S. Food and Drug Administration granted Fast Track Designation to Erasca's ERAS-0015 for the treatment of patients with metastatic pancreatic adenocarcinoma.11d agoA class action lawsuit has been filed against Erasca, Inc. on behalf of investors who purchased Erasca securities between January 14, 2025 and April 26, 2026.30d ago